New medicine for BK virus after kidney transplant
Part of Infections, Kidney & urinary clinical trials.
This study tests a new, unlicensed medicine (AIC468) to see if it can reduce BK virus levels in kidney transplant patients. BK virus can sometimes harm the new kidney, so this treatment aims to lower the virus and protect the transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have had a kidney transplant within the last 12 months.
- You have BK virus in your blood (first time since transplant) at a certain level, as confirmed by blood tests.
- You are not pregnant or breastfeeding, and you agree to use effective birth control during the study.
- You have normal kidney and liver function (based on blood tests).
- You are not already taking certain antiviral drugs or immunosuppressants that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is creating a registry to learn how the immune system responds to BK virus in people who have recently received a kidney transplant from a deceased donor. Researchers hope this information will help improve treatment for BK virus infections.
This study looks at the type and genetic makeup of BK virus in kidney transplant patients and their donors. It aims to find patients at higher risk for a kidney infection caused by the virus, which could help improve monitoring and treatment.
This study tests a new treatment using lab-made antibodies to treat BK virus infection. It may help by controlling the virus in adults who already test BK positive.
This trial tests a treatment using special immune cells (called cytotoxic T lymphocytes) to fight BK or JC virus infections in people with weakened immune systems, such as cancer patients or organ transplant recipients. It may help control the virus and reduce related complications.
This Phase 3 trial tests IVIG (an antibody medicine given through a vein) to treat BK virus infection after kidney or pancreas-kidney transplant. It may help lower the BK virus in the blood and protect the transplanted kidney.
This Phase 1/2 study tests lab-made immune cells that specifically target BK virus in people whose BK infection keeps coming back or doesn’t improve. It may help by boosting the body’s ability to clear the virus, especially when standard antiviral treatments don’t work or can’t be tolerated.
Hear when a new BK Virus Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.